CPIX - カンバ―ランド・ファ―マシュ―ティカルズ (Cumberland Pharmaceuticals Inc.) カンバ―ランド・ファ―マシュ―ティカルズ

 CPIXのチャート


 CPIXの企業情報

symbol CPIx
会社名 Cumberland Pharmaceuticals Inc (カンバ―ランド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 カンバーランド・ファーマシューティカルズ(Cumberland Pharmaceuticals Inc.)はブランド付き処方薬製品の取得、開発及び商品化に従事する医薬品専門会社である。同社は病院ケアと消化器市場向けの処方薬製品を開発・商業化する権利の取得を中心を行う。同社の製品ポートフォリオには、アセトアミノフェン中毒向けの治療薬「Acetadote」(アセチルシステイン)注射剤、疼痛・発熱向けの注射治療薬「Caldolor」(イブプロフェン)注射剤、下剤の処方薬の1種である経口液剤「Kristalose」(ラクツロース)、並びに肝腎症候群(HRS)を患っている患者の治療のための注射剤「Hepatoren」(イフェトロバン)が含まれる。平成23年12月31日現在、「Hepatoren」は第II相臨床開発段階における。平成23年11月、同社は「Kristalose」ブランドと関連する残る権利を取得した。平成23年12月期決算期において、同社は「Hepatoren」ブランド名で開発する後期段階の製品候補の権利を取得した。   カンバ―ランド・ファ―マシュ―ティカルズは米国の医薬品会社。処方箋薬の買収、開発、商業化を行う。主に救急薬と胃腸薬に重点を置く。主な製品はアセトアミノフェン中毒治療用注射剤「アセタド―テ」、急性疼痛・発熱治療用静脈内投与イブプロフェン「カルドロ―ル」など。   Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.
本社所在地 2525 West End Avenue Suite 950 Nashville TN 37203 USA
代表者氏名 A. J. Kazimi A.J.カジミ
代表者役職名 Chairman of the Board Principal Executive Officer
電話番号 +1 615-255-0068
設立年月日 36161
市場名 NASDAQ National Market System
ipoyear 2009年
従業員数 84人
url www.cumberlandpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cpix
adr_tso
EBITDA EBITDA(百万ドル) -2.33567
終値(lastsale) 5.8
時価総額(marketcap) 90295090.2
時価総額 時価総額(百万ドル) 89.20532
売上高 売上高(百万ドル) 41.59758
企業価値(EV) 企業価値(EV)(百万ドル) 50.49531
当期純利益 当期純利益(百万ドル) -4.84351
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cumberland Pharmaceuticals Inc. revenues increased 2% to $18.8M. Net loss before extraordinary items decreased 50% to $3.2M. Revenues reflect Caldolor increase of 22% to $6.5M Vaprisol increase of 85% to $1.8M Kristalose increase of 15% to $2.1M. Lower net loss reflects Selling and Marketing decrease of 2% to $9.7M (expense) Interest Income increase of 90% to $232K (income).

 CPIXのテクニカル分析


 CPIXのニュース

   Cumberland stock soars 15% on launch of antibiotic Vibativ in Middle East  2022/03/31 14:47:23 Seeking Alpha
Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX) and Riyadh, Saudi Arabia-based pharmaceutical company Tabuk Pharmaceutical Manufacturing Company launched…
   Cumberland Pharmaceuticals Inc.''s (CPIX) CEO A.J. Kazimi on Q4 2021 Results - Earnings Call Transcript  2022/03/09 04:08:10 Seeking Alpha
   Cumberland Pharmaceuticals GAAP EPS of -$0.29 misses by $0.26, revenue of $8.3M misses by $32.67M  2022/03/08 21:43:00 Seeking Alpha
Cumberland Pharmaceuticals press release (CPIX): FY GAAP EPS of -$0.29 misses by $0.26.Revenue of $8.3M (-19.1% Y/Y) misses by $32.67M.
   CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2021 FINANCIAL RESULTS  2022/03/01 21:05:00 PR Newswire
NASHVILLE, Tenn., March 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release annual 2021 financial results and provide a company update after the market closes on Tuesday, March 8, 2022. A…
   Stupefying stocks: Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX -16.61%), Lufax Holding Ltd (NYSE:LU -4.43%)  2021/12/10 00:04:49 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Stupefying stocks: Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX -16.61%), Lufax Holding Ltd (NYSE:LU -4.43%) appeared first on Stocks Equity .
   Stupefying stocks: Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX -16.61%), Lufax Holding Ltd (NYSE:LU -4.43%)  2021/12/10 00:04:49 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Stupefying stocks: Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX -16.61%), Lufax Holding Ltd (NYSE:LU -4.43%) appeared first on Stocks Equity .
   Cumberland Pharmaceuticals (NASDAQ:CPIX) Upgraded to C- by TheStreet  2021/12/08 13:34:41 Dakota Financial News
TheStreet upgraded shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) from a d rating to a c- rating in a report published on Monday morning, TheStreetRatingsTable reports. Shares of NASDAQ:CPIX opened at $5.72 on Monday. Cumberland Pharmaceuticals has a 1 year low of $2.20 and a 1 year high of $7.51. The company has a debt-to-equity ratio of []
   Cumberland Pharmaceuticals Reports FDA Approval for Caldolor  2021/11/30 18:01:19 Financial Buzz
Cumberland Pharmaceutical Inc. (NASDAQ: CPIX) has announced that the U.S. Food and Drug Administration has approved expanded labeling for Caldolor, a formulation of ibuprofen, to include use in pre-operative administration. The FDA approved label includes information on the products indications and usage with appropriate patient populations, clinical study results, side effects, safety details and instructions The post Cumberland Pharmaceuticals Reports FDA Approval for Caldolor first appeared on Financial Buzz .
   Thinking about buying stock in Cumberland Pharmaceuticals, AT&T, Clarus Therapeutics, RLX Technology, or Norwegian Cruise Line?  2021/11/30 16:27:00 Benzinga
NEW YORK , Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CPIX, T, CRXT, RLX, and NCLH. Full story available on Benzinga.com
   Read Why Shares Of Nano Cap Cumberland Pharma More Than Doubled  2021/11/30 12:52:02 Benzinga
The FDA has approved expanded labeling for Cumberland Pharmaceuticals Inc''s (NASDAQ: CPIX ) Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration. The non-narcotic pain reliever can now be administered just before surgery to enable patients to wake up from their procedure in significantly less pain. Supporting Full story available on Benzinga.com
   Cumberland Pharmaceuticals Reports FDA Approval for Caldolor  2021/11/30 18:01:19 Financial Buzz
Cumberland Pharmaceutical Inc. (NASDAQ: CPIX) has announced that the U.S. Food and Drug Administration has approved expanded labeling for Caldolor, a formulation of ibuprofen, to include use in pre-operative administration. The FDA approved label includes information on the products indications and usage with appropriate patient populations, clinical study results, side effects, safety details and instructions The post Cumberland Pharmaceuticals Reports FDA Approval for Caldolor first appeared on Financial Buzz .
   Thinking about buying stock in Cumberland Pharmaceuticals, AT&T, Clarus Therapeutics, RLX Technology, or Norwegian Cruise Line?  2021/11/30 16:27:00 Benzinga
NEW YORK , Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CPIX, T, CRXT, RLX, and NCLH. Full story available on Benzinga.com
   Read Why Shares Of Nano Cap Cumberland Pharma More Than Doubled  2021/11/30 12:52:02 Benzinga
The FDA has approved expanded labeling for Cumberland Pharmaceuticals Inc''s (NASDAQ: CPIX ) Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration. The non-narcotic pain reliever can now be administered just before surgery to enable patients to wake up from their procedure in significantly less pain. Supporting Full story available on Benzinga.com
   20 Stocks Moving In Tuesday''s Pre-Market Session  2021/11/30 11:46:32 Benzinga
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) rose 117.3% to Full story available on Benzinga.com
   Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Sees Large Decline in Short Interest  2021/11/29 07:12:41 Transcript Daily
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) saw a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 4,000 shares, a decrease of 95.4% from the October 31st total of 87,000 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily []

 関連キーワード  (医薬品 米国株 カンバ―ランド・ファ―マシュ―ティカルズ CPIX Cumberland Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)